These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 24789000)
1. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. Cantini F; Niccoli L; Goletti D J Rheumatol Suppl; 2014 May; 91():47-55. PubMed ID: 24789000 [TBL] [Abstract][Full Text] [Related]
2. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia. Navarra SV; Tang B; Lu L; Lin HY; Mok CC; Asavatanabodee P; Suwannalai P; Hussein H; Rahman MU Int J Rheum Dis; 2014 Mar; 17(3):291-8. PubMed ID: 24131578 [TBL] [Abstract][Full Text] [Related]
3. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries. Cantini F; Niccoli L; Goletti D J Rheumatol Suppl; 2014 May; 91():56-64. PubMed ID: 24789001 [TBL] [Abstract][Full Text] [Related]
4. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Atzeni F; Sarzi-Puttini P; Botsios C; Carletto A; Cipriani P; Favalli EG; Frati E; Foschi V; Gasparini S; Giardina A; Gremese E; Iannone F; Sebastiani M; Ziglioli T; Biasi D; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Gorla R; Govoni M; Lapadula G; Marchesoni A; Salaffi F; Punzi L; Triolo G; Ferraccioli G Autoimmun Rev; 2012 Dec; 12(2):225-9. PubMed ID: 22796281 [TBL] [Abstract][Full Text] [Related]
5. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study. de la Torre I; Valor L; Nieto JC; Montoro M; Carreño L Reumatol Clin; 2014; 10(2):101-4. PubMed ID: 24280444 [TBL] [Abstract][Full Text] [Related]
6. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up. Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496 [TBL] [Abstract][Full Text] [Related]
7. [Meta analysis of infection risks of anti-TNF-α treatment in rheumatoid arthritis]. Xie X; Chen J; Peng Y; Gao J; Tian J; Ling G; Du J; Mao N; Wu P; Li F Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jul; 38(7):722-36. PubMed ID: 23908082 [TBL] [Abstract][Full Text] [Related]
8. The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies. Ai JW; Zhang S; Ruan QL; Yu YQ; Zhang BY; Liu QH; Zhang WH J Rheumatol; 2015 Dec; 42(12):2229-37. PubMed ID: 26472414 [TBL] [Abstract][Full Text] [Related]
9. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849 [TBL] [Abstract][Full Text] [Related]
10. Problems encountered during anti-tumour necrosis factor therapy. Desai SB; Furst DE Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537 [TBL] [Abstract][Full Text] [Related]
11. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD; Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464 [TBL] [Abstract][Full Text] [Related]
12. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328 [TBL] [Abstract][Full Text] [Related]
13. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Tubach F; Salmon D; Ravaud P; Allanore Y; Goupille P; Bréban M; Pallot-Prades B; Pouplin S; Sacchi A; Chichemanian RM; Bretagne S; Emilie D; Lemann M; Lortholary O; Mariette X; Arthritis Rheum; 2009 Jul; 60(7):1884-94. PubMed ID: 19565495 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M; Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089 [TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis. Chen JS; Makovey J; Lassere M; Buchbinder R; March LM Arthritis Care Res (Hoboken); 2014 Mar; 66(3):464-72. PubMed ID: 24022870 [TBL] [Abstract][Full Text] [Related]
16. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743 [TBL] [Abstract][Full Text] [Related]
17. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Dixon WG; Hyrich KL; Watson KD; Lunt M; Galloway J; Ustianowski A; ; Symmons DP; Ann Rheum Dis; 2010 Mar; 69(3):522-8. PubMed ID: 19854715 [TBL] [Abstract][Full Text] [Related]
18. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133 [TBL] [Abstract][Full Text] [Related]
20. Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy. Suh YS; Kwok SK; Ju JH; Park KS; Park SH; Yoon CH J Korean Med Sci; 2014 Jan; 29(1):38-42. PubMed ID: 24431903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]